The place of chemotherapy in the treatment of early breast cancer

British Journal of Cancer

Volumn 78, Issue SUPPL. 4, 1998, Pages 16-20

  Buzdar, A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemotherapy; Early breast cancer; Endocrine therapy; Tamoxifen

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FLUOXYMESTERONE; MELPHALAN; METHOTREXATE; PREDNISONE; TAMOXIFEN; THIOTEPA; VINBLASTINE; VINCRISTINE;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; EARLY CANCER; HEALTH STATUS; HEART DISEASE; HUMAN; MENOPAUSE; MORBIDITY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; NEOPLASM STAGING; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 0031686897     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.757     Document Type: Article

References (26)

1. Bearman SI, Shpall EJ, Jones RB, Cagnoni PJ and Ross M (1996) High dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer. Semin Oncol 23(suppl. 2): 60-67
2. Bonadonna G and Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10-15
3. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetla E, Musumeci R, Veronesi V (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405-410
4. Bonadonna G, Zambetti M and Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. J Am Med Assoc 273: 542-548
5. Buzdar AU, Marcus C, Smith TL and Blumenschein GR (1985) Early and delayed clinical toxicity of doxorubicin. Cancer 55: 2761-2765
6. Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Gutterman JU, Hug VM, Singletary SE, Ames FC (1992) Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J Clin Oncol 10: 1540-1546
7. Buzdar AU, Hortobagyi GN, Singletary SE, Holmes FA, Theriault R, Walters R, Dhingra K, Booser D, Morris A, Asmar L, Wright-Browne V, Diamandidou E, Wijzaksono MA, Strom E, McNeese M, Ames F (1997) Impact of FAC adjuvant therapy on mortality of early breast cancer: long-term results of the MD Anderson Cancer Center Studies. In Adjuvant Therapy of Cancer VIII. Salmon SS (ed.), pp. 93-100. Lippincott-Raven: Philadelphia.
8. Buzdar AU, Hortobagyi GN, Singletary SE, Theriault R, Booser D, Asmar L, McNeese M, Strom E, Ames F (1998) Long-term efficacy data of FAC-adjuvant therapy in breast cancer - a single institution's experience (abstract 455). Proc Am Soc Clin Oncol (in press)
9. Coombes RC, Bliss JM, Wils J, Morvan F, Espie M, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Perez-Lopez FR, Vassilopoulos P, Ferreira EP, Chilvers CE, Coombes G, Woods EM, Marty M (1996) Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 14: 35-45
10. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 71-85
11. Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL, Wolmark N, Fisher ER (1975) L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 292: 117-122
12. Fisher B, Fisher ER and Redmond C (1986) Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 4: 929-941
13. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen non-responsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 [prior annotation incorrect]. J Clin Oncol 8: 1483-1496
14. Fisher B, Dignam J, Bryant J, De Cillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529-1542
15. Fisher B, Dignam J, Wolmark N, De Cillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89: 1673-1682
16. Garne JP, Aspegren K, Balldin G and Ranstam J (1997) Increasing incidence of declining mortality from breast carcinoma. Trends in Malmö, Sweden, 1961-1992. Cancer 79: 69-74
17. Landis SH, Murray T, Bolden S and Wingo PA (1998) Cancer statistics 1998. Ca Cancer J Clin 48: 6-29
18. Levine M, Bramwell V, Bowman D, Norris B, Findlay B, Warr D, Pritchard KI, MacKenzie R, Robert J, Arnold A, Tonkin K, Shepherd L, Ottaway J, Myles J (1995) A clinical trial of intensive CEF versus CMF in premenopausal women with node positive breast cancer. Proc Am Soc Clin Oncol 14: 103
19. Misset JL, di Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P, Le Mevel B, Belpomme D, Guerrin J, Fargeot P, Metz R, Ithzaki M, Hill C, Mathe G (1996) Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol 14: 1136-1145
20. Olivotto IA, Bajdik CD, Plenderleith IA, Coppin CM, Gelmon KA, Jackson SM, Ragaz J, Wilson KS, Worth A (1994) Adjuvant systemic therapy and survival after breast cancer. N Engl J Med 330: 805-810
21. Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb A, Aust JC, Bank A, Silver RT, Saleh F, Canellos GP, Perry MC, Weiss RB, Holland JF (1996) Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol 14: 1589-1598
22. Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S and Pater J (1996) Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site group. J Clin Oncol 14: 2731-2737
23. Quinn M and Allen E (1995) Changes in incidence of and mortality from breast cancer in England and Wales since the introduction of screening. United Kingdom Association of Cancer registries. Br Med J 311: 1391-1395
24. Swedish Breast Cancer Cooperative Group (1996) Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88: 1543-1549
25. Wolmark N, Fisher B and Anderson S (1997) The effect of increasing dose intensity and cumulative dose of adjuvant cyclophosphamide in node positive breast cancer: results of NSABP B-25 (abstract 16). Breast Cancer Res Treat 46: 26
26. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast cancer. N Engl J Med 330: 1253-1259